{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64","upperLimit":"99.8","value":"92"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"CR as per International Myeloma Working Group (IMWG) uniform criteria is defined as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and \\<5% plasma cells in bone marrow. Partial response(PR):\\>=50% reduction of serum M-protein,urinary M-protein by \\>=90%/to \\<200 mg/24 hr reduction.Near CR(nCR):positive immunofixation of serum/urine;soft tissue plasmacytomas disappearance;\\<=5% plasma cells in bone marrow. VGPR as per IMWG criteria is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hours. VGPR was applicable only to participants who had measurable disease defined by at least 1 of the following 3 measurements: Serum M-protein greater than or equal to (\\>=)1 g/dL; Urine M-protein \\>=200 mg/24 hours; Serum FLC assay level \\>=10 mg/dL, provided serum FLC ratio was abnormal.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 3 mg, capsules, orally, twice-weekly on Days 1, 4, 8, and 11, lenalidomide 25 mg, capsules, orally, once daily on Days 1-14, dexamethasone 20 mg, capsules, orally, once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 in Cycle 1-8 and dexamethasone 10 mg, capsules, orally, once daily on Days 1, 2, 4, 5, 8, 9, 11, and 12 in Cycle 9-16 in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly on Days 1, 4, 8, and 11 in 21-day treatment cycles as maintenance therapy at the dose tolerated at the end of induction until progressive disease or unacceptable toxicity. The maximum number of cycles received was 83 cycles (approximately up to 2037 days).","id":"OG000","title":"Phase 1: Ixazomib 3 mg"}],"paramType":"NUMBER","populationDescription":"Response-evaluable population included all participants who received at least 1 dose of ixazomib, had measurable disease at baseline, and at least 1 post-baseline disease assessment. Results were summarized together for all Phase 1 participants, as per planned analysis.","reportingStatus":"POSTED","timeFrame":"Baseline until end of study treatment (Up to treatment Cycle 83 - approximately 2037 days)","title":"Phase 1: Percentage of Participants With Best Overall Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}